Latest Operational Expansion News

RLF AgTech reported a 5% increase in revenue to $14.3 million for the half-year ending December 2025, while posting a $4.08 million loss reflecting a deliberate investment phase. The company also appointed Stuart Upton as CEO to lead its next growth chapter.

Murray Cod Australia Ltd reported a 40% revenue increase to $6.69 million for H1 2026 but swung to a $4.06 million net loss, reflecting significant investments and operational expansion.

Advanced Energy Minerals reports a sharp revenue increase alongside a substantial net loss for 2025, completing a major plant expansion and raising $44.8 million in its IPO.

Metal Powder Works Limited reported a substantial increase in its half-year loss to $3.7 million, driven by investments in production scaling and market expansion. Revenue more than doubled, reflecting strong demand in defence, aerospace, and nuclear sectors.

NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.

Qoria Limited reported a 25% revenue increase to nearly $69 million for H1 FY2026 but also a widening net loss of $24.5 million. The company announced a transformative merger with US-based Aura to create a global digital safety leader.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

EMVision Medical Devices reported a $3.97 million loss for H1 2026, up 11% year-on-year, driven by increased share-based payments and expanded clinical activities. The company secured a $3 million government grant to advance stroke diagnosis in regional Australia.

LGI Limited reported robust half-year results for December 2025, showcasing strong revenue and profit growth alongside operational expansion and strategic debt repayment.

Austral Resources Australia Ltd has resumed trading on the ASX following news of a significant capital raising and a strategic investor commitment, signaling renewed confidence in the company’s future.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.